Skip to content
IP + Technology Law
Christopher Lewis - Washington D.C.

Christopher L. Lewis

Associate
Washington DC
christopher.lewis@knobbe.com
202-640-6400
vcard iconDownload vCard

Overview

Christopher L. Lewis’s practice focuses on representing clients in intellectual property disputes involving patents, trademarks, and trade secrets. He has experience in the medical device, software, and robotics areas.

Christopher graduated cum laude from Clemson University, receiving a Bachelor’s Degree in Electrical Engineering with a Minor in Mathematics. While an undergraduate, Christopher interned at a nuclear power plant for a Fortune 500 power holding company. His undergraduate thesis focused on implementing new hardware and software for a robotic elephant trunk.

Christopher received his J.D. from Wake Forest University where he was a member of the Wake Forest Journal of Business and Intellectual Property Law. While at Wake Forest, Christopher worked as a research librarian and volunteered at the local expungement clinic.

Christopher worked as a summer associate at the firm in 2018 and joined the firm in 2019.

Education

  • Clemson University (B.S. Electrical Engineering, 2016), General Honors, Departmental Honors, Cum Laude
  • Wake Forest University School of Law (J.D., 2019), Cum Laude

Bar Admissions

  • State Bar of North Carolina

Recognition

Awards & Honors

  • Recognized as a “Washington D.C. Super Lawyer” by Super Lawyers magazine for his intellectual property litigation practice (2023)

News & Insights

Articles

Latest Updates and News

News
Apr 2024
Washington D.C. Super Lawyers Recognizes Several Knobbe Martens Attorneys
WASHINGTON, D.C., April 23, 2024 – Knobbe Martens congratulates partner William Zimmerman and associates Justin Culbertson and Christopher Lewis on being recognized by Washington, D.C. Super Lawyers. Mr. Zimmerman was...
Blog - Medical Devices & Procedures
Sep 2023
Venture Capitalist Funding in Medtech Increasing
Recent reports, including one by PitchBook, indicate that both venture capitalist funding for medtech companies and the variety of medtech companies receiving venture capitalist funding has increased since the first quarter of 2023.
Blog - Litigation
Sep 2022
Judicial Review: The PTAB Must Offer Reasonably Discernible Logic
PROVISUR TECHNOLOGIES, INC. v. WEBER, INC. Before Prost, Reyna, and Stark. Appeal from the Patent Trial and Appeal Board. Summary: The PTAB has an obligation to ensure that its logic is reasonably discernible from the record. Weber petitioned for inter partes review of Provisur’s patent, arguing that the claims were invalid as obvious over multiple references. With its reply brief, Weber also submitted evidence that the digital camera disclosed in Weber’s references was the same type of camera claimed by Provisur’ patent.
Blog - Medical Devices & Procedures
Sep 2022
Medtronic Completes Acquisition of Cardiac Mapping Company Affera
Medtronic recently announced that its acquisition of Affera, Inc. has been completed. The acquisition was previously announced to be for $925 million with a $250 million contingency, as reported by MedCity News. Medtronic had previously been a strategic investor in Affera and, prior to the acquisition, owned a 3% interest in Affera as stated in a prior press release dated January 10, 2022.
Blog - Litigation
May 2022
Somebody’s Wrong: PTAB Must Resolve Conflicting Factual Testimony During IPR
GOOGLE LLC v. IPA TECHNOLOGIES INC. Before Dyk, Schall, and Taranto. Appeal from the Patent Trial and Appeal Board. Summary: For purposes of determining whether a reference was prior art, the Board has an obligation to resolve fundamental testimonial conflicts.
Blog - Medical Devices & Procedures
May 2022
Pfizer Australia Announces Deal to Acquire ResApp Health
ResApp Health recently announced its planned sale to Pfizer Australia, a wholly owned subsidiary of Pfizer Inc. Pfizer agrees it would acquire 100% of the shares for AUD $0.115 / share, for a total equity value of approximately AUD $100 million. ResApp directors announced a unanimous recommendation to sell, and their intent to vote their own shares accordingly. A shareholder vote is scheduled for June.